AARDEX still confirms its leading position in the B2B medication adherence market, closing steadily more new deals with Pharma Companies, Biotech’s, Excellence Centers and Universities, over 30 countries in 2018.

AARDEX still confirms its leading position in the B2B medication adherence market, closing steadily more new deals with Pharma Companies, Biotech’s, Excellence Centers and Universities, over 30 countries in 2018.
You’ll often hear the terms “adherence” and “compliance” used as if they mean the same thing. But in healthcare and clinical research, they carry very different meanings. Understanding that difference can change the way we work with patients, design better
Liège, Belgium and Manchester, UK; August 2025: AARDEX Group, a global leader in digital medication adherence solutions, and Pill Connect, a pioneer in connected dispensing technology, have announced a strategic partnership to support a multi-cohort Phase 2A dose selection trial.